X4 Pharmaceuticals Plans Phase 2b Mavorixafor Trial for Q1 2027
X4 Pharmaceuticals plans a Phase 2b mavorixafor trial in chronic neutropenia for Q1 2027.
Related stories
AstraZeneca CEO Sees Over $20 Billion in Potential Sales From 2027 Trial Readouts
CEO Pascal Soriot said 2027 drug trial readouts could generate over $20 billion in peak annual sales. The company also unveiled a restructuring program targeting $1.5 billion in an
M impact | EQUITY | Oct 30, 2026, 11:38 AM UTC
Cboe Global Markets Reports Third-Quarter Results
Cboe Global Markets reported third-quarter diluted EPS of $4.08, up 43 percent.
M impact | EQUITY | Oct 30, 2026, 11:33 AM UTC
Hinduja Housing Finance Appoints Vivek Kannan CEO
Kannan succeeds Sachin Pillai and will oversee business performance, operations, risk and growth. He previously served as the company’s chief operating officer.
M impact | EQUITY | Oct 30, 2026, 11:32 AM UTC
Acumen Pharmaceuticals shares fall 75% premarket
Acumen Pharmaceuticals (ABOS) shares fell 75% before the market open.
H impact | EQUITY | Oct 30, 2026, 11:31 AM UTC
Asian Stocks Fall, Led by South Korea’s Kospi
Japan’s Nikkei 225 dropped 2.1% to 63,290.11, the Topix fell 1%, South Korea’s Kospi declined around 3.5%, and mainland China’s Shanghai Composite was down 1.4%. Semiconductor manu
M impact | EQUITY | Oct 30, 2026, 11:31 AM UTC
Federal Realty Reports Third-Quarter Revenue of $339M
M impact | EQUITY | Oct 30, 2026, 11:30 AM UTC